Immunovaccine Presents at Two International Scientific Conferences
HALIFAX, NOVA SCOTIA -- (MARKET WIRE) -- 04/05/11 -- Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine developer, announced today that it will present at the American Association for Cancer Research (AACR) 102nd annual meeting in Orlando, FL and at the World Vaccine Congress 2011 in Washington, D.C. Presentations will disclose findings from the Phase I clinical trial with the therapeutic cancer vaccine, DPX-0907, and the ability of Depovax to enhance the immunogenicity of peptide antigens.
At AACR, Marc Mansour, Ph.D., Vice President of R&D, will deliver a poster presentation titled "Evaluation of the clinical safety of DPX-0907, a multi-epitope vaccine for the treatment of breast, ovarian and prostate cancers" on Wednesday, April 6, 2011 from 8:00 am - 12:00 pm ET at Exhibit Hall A4-C, Poster Section 32, Abstract Number 5534. The annual AACR meeting highlights the latest discoveries and developments in oncology research.
At the World Vaccine Congress, Dr. Mansour will present synthetic peptide based vaccine strategies for therapeutic cancer applications on Thursday, April 14, 2011 at 1:40 pm ET. A white paper titled "Delivery of peptide antigens using DepoVax, a vaccine enhancement platform" will be submitted. The World Vaccine Congress is a definitive event for major vaccine players.
Please note that all data is embargoed until after the presentations and will be available on Immunovaccine's website at www.deliveringbreakthroughs.com.
Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Immunovaccine Inc. Jennifer Ayotte Director Communications (902) 492-1819 email@example.com www.imvaccine.com Tiberend Strategic Advisors, Inc. Andrew Mielach (212) 827-0020 firstname.lastname@example.org
Source: Immunovaccine Inc.
Released April 5, 2011